March 15, 2021

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub:** Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Potassium Chloride for Oral Solution”

Thanks & Regards,
For **Strides Pharma Science Limited**,  
Manjula Ramamurthy  
Company Secretary

Encl. As above
Bengaluru, March 15, 2021 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride for Oral Solution USP, 20 mEq, of Pharma Research Software Solution, LLC.

According to IQVIA MAT January 2021 data, the US market for Potassium Chloride for Oral Solution USP, 20 mEq is approximately US$ 56 Mn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with USFDA of which 100 ANDAs have been approved and 27 are pending approval.

About Potassium Chloride for Oral Solution
Potassium Chloride Oral Solution is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>Corporate Communication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur</td>
<td>Usha Iyer: +91 99874 44106</td>
</tr>
<tr>
<td>Executive Director – Finance &amp; Group CFO</td>
<td>Email: <a href="mailto:usha.iyer@strides.com">usha.iyer@strides.com</a></td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investor Relations</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandeep Baid: +91 80 6784 0791</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>Email: <a href="mailto:Sandeep.baid@strides.com">Sandeep.baid@strides.com</a></td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
</tbody>
</table>